All the Active Ingredient Drugs
α2 Agonist. Brimonidine Tartrate 0.15% w/v. OPHTH. SOLN: 5 ml. 1 drop 2 x dly.
When IOP peaks in afternoon or
additional IOP control need: 1 drop
may be added in the afternoon. May
be used concom. with other ophth.
prods. to be admin. at least 5 mins
apart. Not recommend. child 2-12 yrs.
Lower. IOP with open-angle glaucoma or
C/I: Known hypersens., pts. receiving
MAOI’s; lactation; child under 2 yrs.
α2 Agonist, β Blocker. Brimonidine Tartrate 2 mg/ml, Timolol Maleate 5 mg/ml. OPHTH. SOLN: 5 ml. 1 drop in affect.
eye/s 2 x dly (± every 12 hrs.). If using
more than one top. ophth. soln, use 10
Chron. open-angle glaucoma, ocular
hypertens. not suffic. respond. to IOP
reduct. monother. or use not appropriate.
C/I: Hypersens., bronch. asth./history
thereof, severe chron. obstruct. pulm.
dis., sinus bradycard., 2nd/3rd degree
atrioventric block, overt card. fail.,
cardogen shock, MAOI ther.
Carbonic Anhydrase Inhibitor, α2 Agonist. Brinzolamide 10 mg/ml, Brimonidine Tartrate 2 mg/ml. BOTTLE: 5 ml. 1 dr×2/d in the affected eye(s). See lit.
Decrease of elevated intraoc. pressure (IOP) in adult pts. with open-ang. glauc. or ocular hypertens. for whom monotherapy provides insuffic. IOP reduct.
C/I: Hypersens. Hypersens. to sulphonamides. Pts. receiving MAO inhib.
Pts on antidepressant. which affect noradrenergic transmission (e.g. TCA's & mianserin). Pts. with severe renal impair. Pts. with hyperchloraemic acidosis.
Neonates & infants under the age of 2 yrs.